

CREATING TRANSFORMATIVE, FIRST-IN-CLASS ANTI-INFECTIVES FOR LIFE-THREATENING VIRAL AND BACTERIAL RESPIRATORY INFECTIONS

COMPANY OVERVIEW

Aridis Pharmaceuticals is advancing multiple clinical stage monoclonal antibodies (mAbs) targeting bacteria that cause life-threatening infections such as ventilator associated pneumonia (VAP) and hospital acquired pneumonia (HAP), in addition to preclinical stage antiviral mAbs. The use of mAbs as anti-infective treatments represents an innovative therapeutic approach that harnesses the human immune system to fight infections and is designed to overcome the deficiencies associated with the current standard of care which is broad spectrum antibiotics. Such deficiencies include, but are not limited to, increasing drug resistance, short duration of efficacy, disruption of the normal flora of the human microbiome and lack of differentiation among current treatments. The mAb portfolio is complemented by a non-antibiotic novel mechanism small molecule anti-infective candidate being developed to treat lung infections in cystic fibrosis patients.

INVESTMENT HIGHLIGHTS

- Unique, novel approach using human-derived mAbs to treat infectious diseases
- Addressing \$1B+ opportunity with lead drug candidate AR-301
- Reported positive data from two late-stage trials in QI 2023
- AR-301: first of two planned Phase 3 trials; received agreement from FDA on single confirmatory Phase 3 study design in May 2023
 - AR-501: met primary and secondary endpoints
- Received \$1.9M grant from the Bill & Melinda Gates Foundation to evaluate inhaled monoclonal antibodies against influenza and COVID-19
- Received \$12.5M in grant and equity funding from the Cystic Fibrosis Foundation to develop treatment for CF patients with pneumonia
- World-class team of senior executives:
 - CEO, Director Vu Truong; Medimmune, Aviron
 - Chief Medical Officer Hasan Jafri; AstraZeneca, Medimmune
 - Director Robert Rufolo- Wyeth/Pfizer; Craig Gibbs- Gilead; Eric Patzer-Genentech

VALUE PROPOSITION

Aridis is revolutionizing how we treat infectious diseases through its unique technology platforms, which can quickly detect human-derived mAbs to treat infectious diseases. The Company's transformative approach utilizes a patient's own immune system to identify mAbs capable of fighting infections and underpins multiple late-stage programs. In January, Aridis announced positive top-line data from the first of two Phase 3 studies of its lead candidate, AR-301, for the treatment of VAP caused by Gram-positive bacteria Staphylococcus aureus (S. aureus). In March, Aridis announced positive top-line data from its Phase 2a trial in cystic fibrosis, meeting primary and second endpoints for the study. Aridis received agreement from the FDA for a single confirmatory Phase 3 study of AR-301 in May 2023 and is discussing results of its CF study with the FDA and the EMA to plan the definitive next steps. The Cystic Fibrosis Foundation is the largest shareholder of Aridis and has invested \$12.5 million into the Company to date.

(OTC: ARDS)

Aridis Pharmaceuticals, Inc. HQ: Los Gatos, CA Leadership Team CEO & Founder: Vu Truong, PhD CFO: Fred Kurland CMO: Hasan Jafri, MD

Auditors: Mayer Hoffman McCann PC Legal: Sheppard, Mullin, Richter & Hampton

MARKET DATA

Price ¹	\$0.31
52-wk Range ¹	\$0.15 - \$2.77
Market Cap ¹	\$11.2M
Shares Outstanding ¹	36.1M
Float ¹	24.7M
Avg. Volume (90-day) ¹	4.6M
Insider Ownership ¹	31.5%
Cash (mrq) ²	\$1.3
LT Debt (mrq) ²	\$0.0M

Fiscal Year: December 31

¹ as of July 19, 2023 ² as of December 31, 2022

www.aridispharma.com

RetChip Companies, Inc. research reports, company profiles and their investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investorment needs of any investor. Any options expressed in RedChip companies, and its affiliates may buy and reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investorment needs of any investor. The information contained herein is not intended to be used as the basis for investiment needs of any investor. The information contained herein is not a representation or warranty and is and instantion or warranty and is not an other or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., com specialists, advisors, and partners will not be aliable barny person or entity (not the quality, accuracy, completeness, reliability or timelines of the information provided to any person or entity (notified) but for this, RedChip Companies is not respecial or puritive demages that may arise out of the use of any investores of the information provided to any person or entity (notified) but for thinks, RedChip Companies is not respective). This office materials publications materials on the onions expressed on information provided to any person or entity (notified) but for the low intende to low profits. So of opportunities, candidan but expressed on the velocities expressed on information provided to any person or entity (notified) but for the low intende to low profits. In the opponies is not respective that publications materials on the provide expressed on the velocities expressed on the velocities expressed on the velocities expressed on the velocit expresse